MRK

MerckB

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$138.00

+19.3% vs current

Most likely

Base case

50%

Probability

Target price

$126.00

+8.9% vs current

B-

Bear case

20%

Probability

Target price

$98.00

-15.3% vs current

AI sentiment snapshot

Latest data as of 2026-05-03

AI commentary

Near-term news tone improved after the April 30 print: checked coverage framed the quarter as better than expected on strong oncology sales, and Reuters-syndicated coverage indicated shares were up about 4% to 5% premarket immediately after results. With the anchor price at $112.16 on May 1, the follow-through looks positive but not euphoric. Because checked sources did not surface a full T+3 analyst revision set, this still looks more like a constructive monitoring setup than a fully de-risked rerating call.

RankAlpha Sentiment Codex - 2026-05-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31eventPlanned Terns acquisition is a May portfolio-action checkpointMedium impact

Merck said the Terns Pharmaceuticals transaction is expected to close in May and would expand the hematology pipeline with TERN-701, but it also implies an added one-time charge of about $5.8B not reflected in current outlook, so closing terms and investor reception matter [#8-K-2026-04-30].

2026-05-31catalystPost-earnings digestion favors the operational beat despite acquisition chargesMedium impact

Q1 2026 sales rose to $16.3B, KEYTRUDA/KEYTRUDA QLEX reached $8.0B, WINREVAIR reached $525M, and management narrowed and raised the midpoint of full-year sales and non-GAAP EPS guidance; the main near-term question is whether investors keep rewarding the underlying operating beat after adjusting for the Cidara-related loss [#8-K-2026-04-30].

2026-10-10catalystDense six-month milestone calendar can test the post-Keytruda diversification storyHigh impact

Merck's April 30 earnings presentation laid out dated milestones over the next six months, including WELIREG PDUFA on June 19, KEYNOTE-B152 PDUFA on August 17, HYPERION PDUFA on September 21, IDeate-Lung01 PDUFA on October 10, plus HIV and ophthalmology readouts; this is the clearest forward catalyst set supporting the portfolio-transition thesis [#IR-2026-04-30].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-03 • Updated nightlySource: Internal modelMethodology